Vet Biotechnology targets equine disease
21 September, 2004 by Renate KrelleAnimal health and stem-cell company Vet Biotechnology has advanced to the starting gate - and is readying to list on the Newcastle Stock Exchange in late October.
New biotechs head for the NSX
21 September, 2004 by Renate KrelleHaving waved goodbye to its first biotech alumnus Living Cell Technologies (ASX:LCT) earlier this year, the Newcastle Stock Exchange is expecting a number of fresh biotech companies to list on the exchange this year.
Rockeby lines up diagnostics for FDA approval
20 September, 2004 by Renate KrelleRockeby biomed (ASX: RBY) has lodged a 501(k) submission for regulatory approval of its systemic candidiasis diagnostic SysCan3 with the United States Food and Drug Administration.
Capital markets still healthy, say analysts
20 September, 2004 by Melissa TrudingerAnalysts say that the IPO market for biotech companies in Australia is healthy right now, and they don't foresee any problems in the near future.
Bionomics sets up US subsidiary
20 September, 2004 by Melissa TrudingerBionomics (ASX: BNO) has set up a US subsidiary to hold intellectual property coming out of its US collaborations.
Early success for Biosignal's anti-bacterial contact lenses
20 September, 2004 by Renate KrelleBiosignal (ASX:BOS) and the Institute for Eye Research Ltd (IER) have reported interim results from recent in vitro trials of contact lenses with permanently attached furanones.
Alchemia gets results with anti-cancer compound
20 September, 2004 by Melissa TrudingerAlchemia (ASX: ACL) will commence the preclinical studies necessary to take its lead anti-cancer compound into human clinical trials after positive results from studies in an animal model of lung cancer.
GTG shares soar on back of Applera lawsuit news
20 September, 2004 by Renate KrelleThe share price of Genetic Technologies (ASX: GTG) has risen over 50 per cent since the judge in GTG's lawsuit against Applera ruled largely in the company's favour during the Markman hearing last Thursday.
Isis antisense drug delays tumour growth
17 September, 2004 by Staff WritersShares of California-based Isis Pharmaceuticals rose as much as 13 per cent on Thursday after it said its experimental anti-cancer compound significantly delayed tumour growth and increased the rate of malignant cell death in cell and animal models.
New NZ fund set up for agbiotech investment
17 September, 2004 by Renate KrelleA New Zealand-based venture capital fund of between NZ$75-100 million (AUD$70-94.5 million), with a focus on agricultural biotech has been established by the venture capital arm of the NZ government and private collaborators Direct Capital and crown research institute AgResearch.
Avastra investigates using Bioweld for drug deliery
17 September, 2004 by Melissa TrudingerNSW biomaterials company Avastra (ASX: AVS) is investigating the potential of its BioWeld technology -- which uses a protein solder activated by laser light to fuse together blood vessels -- as a drug delivery mechanism.
Biota launches share purchase plan
16 September, 2004 by Melissa TrudingerBiota (ASX:BTA) has launched a share purchase plan, which could raise almost AUD$15 million for the company if fully subscribed.
Imugene expands technology opps with new company
16 September, 2004 by Melissa TrudingerImugene (ASX:IMU) and the University of Adelaide have set up a new company to develop and commercialise human gastrointestinal applications of the receptor mimic technology (RMT), including cholera, rotavirus, 'travellers' diarrhoea', and antibiotic-associated diarrhoea.
Benitec using RNAi to focus on hep C
15 September, 2004 by Graeme O'NeillA senior scientist from Brisbane-based biotech company Benitec (ASX:BLT) has told a conference that there is "incredible excitement" in the biomedical research community about the human therapeutic potential of RNA interference (RNAi) gene-silencing technology.
Chemgenex patents more depression genes
15 September, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (ASX: CXS) has filed patent applications for another five novel depression-associated gene targets, bringing the total number of gene targets with patent protection from the CNS project to 10.
